Key Points
- Surrozen VP Yang Li sold 1,118 shares on Jan. 5 at an average price of $19.87, reducing their holding by 6.50% to 16,091 shares (worth about $319,728).
- The company reported a steep quarterly loss (EPS -$3.61 vs. -$1.17 consensus), just $0.98M in revenue and extremely negative margins and ROE, highlighting weak near-term profitability.
- Institutional investors own about 66.6% of the stock, and analysts are mixed but the consensus rating is "Moderate Buy" with a consensus price target of $32.
Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) VP Yang Li sold 1,118 shares of the business's stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $19.87, for a total value of $22,214.66. Following the completion of the transaction, the vice president owned 16,091 shares in the company, valued at $319,728.17. This trade represents a 6.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Surrozen Price Performance
SRZN opened at $19.67 on Wednesday. The company has a market capitalization of $168.57 million, a PE ratio of -0.88 and a beta of 0.58. Surrozen, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $24.94. The business has a 50-day moving average of $17.64 and a 200-day moving average of $13.39.
Surrozen (NASDAQ:SRZN - Get Free Report) last announced its quarterly earnings results on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The firm had revenue of $0.98 million during the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. On average, equities research analysts expect that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Surrozen
A number of institutional investors have recently added to or reduced their stakes in SRZN. Adage Capital Partners GP L.L.C. raised its stake in shares of Surrozen by 37.1% in the first quarter. Adage Capital Partners GP L.L.C. now owns 88,653 shares of the company's stock valued at $1,034,000 after purchasing an additional 24,000 shares in the last quarter. Stempoint Capital LP boosted its stake in Surrozen by 185.1% during the second quarter. Stempoint Capital LP now owns 686,539 shares of the company's stock worth $6,138,000 after buying an additional 445,713 shares in the last quarter. Braidwell LP acquired a new stake in Surrozen during the second quarter worth $1,252,000. Millennium Management LLC bought a new stake in Surrozen in the 3rd quarter valued at $1,414,000. Finally, Stonepine Capital Management LLC raised its stake in shares of Surrozen by 7.1% in the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company's stock valued at $2,736,000 after buying an additional 20,247 shares in the last quarter. 66.57% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
SRZN has been the subject of several analyst reports. Lifesci Capital raised shares of Surrozen to a "strong-buy" rating in a research note on Thursday, November 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Surrozen in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Surrozen to a "sell" rating in a research note on Friday, November 28th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $32.00.
View Our Latest Stock Analysis on SRZN
About Surrozen
(
Get Free Report)
Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.
The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
